Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GoCAR-NK
- Development stage
- Preclinical
- Lead developer
- Bellicum Pharmaceuticals
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GoCAR-NK is an allogeneic engineered **CAR-NK cell therapy** platform originally developed by Bellicum Pharmaceuticals and later associated with intellectual property acquired by MD Anderson Cancer Center. The platform uses donor-derived natural killer cells engineered to combine antigen-directed chimeric antigen receptor killing with intrinsic NK-cell cytotoxicity. A distinguishing feature is an inducible MyD88/CD40 activation switch that can be triggered by rimiducid to enhance NK-cell activation, proliferation, persistence, and antitumor activity, together with a rapamycin-inducible caspase-9 safety switch intended to allow controlled elimination of the cells if needed. Reported GoCAR-NK programs have included constructs directed against BCMA for multiple myeloma, CD123 for acute myeloid leukemia, and HER2 for solid tumors, with autocrine IL-15 support designed to improve in vivo function and persistence.
- Other names
- GoCAR-NK cell therapyGoCAR-NK platform
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on GoCAR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GoCAR-NK.